Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2009

View Archived Issues

Fenofibric acid plus rosuvastatin increases lipid target attainment in diabetes patients

Phase I and II data on aleglitazar in type 2 diabetes presented

Versartis presents new long-acting candidates at recent congresses

ASCO snapshots: clinical data on treatments for lymphoma and plasma cell disorders disclosed

Crucell presents results of phase II rabies monoclonal antibody trial

CHMP issues positive opinion supporting approval of Pierre Fabre's Javlor for bladder cancer

Wyeth claims PI3K/mTOR inhibitors for the treatment of cancer

GlaxoSmithKline describes hypoxia-inducible factor prolyl hydroxylase inhibitors as antianemics

Jazz and UCB report preliminary results from phase III clinical trial of sodium oxybate

Conatus initiates second phase II clinical trial of CTS-1027 in HCV

Glenmark announces results from phase IIb clinical trial of melogliptin in type 2 diabetes

FDA approves Apthera's SPA for phase III clinical trial of NeuVax in breast cancer

Biotica adds polyketide cyclophilin inhibitors for HCV to pipeline

Cell Therapeutics submits NDA to FDA for pixantrone in non-Hodgkin's lymphoma

Insmed reports results from phase II clinical trial of Iplex in myotonic muscular dystrophy

Pfizer reports results from phase III trial of Sutent in advanced pancreatic islet cell tumors

FDA approves amendment to SPA for a phase III trial of OncoGenex's OGX-011 in CRPC

Santhera and NIH to collaborate on IPPoMS phase I/II trial of Catena in PPMS

Takeda receives FDA complete response letter for alogliptin

Teva and Active Biotech complete enrollment in phase III BRAVO trial of laquinimod

Telmisartan/amlodipine reduces microalbuminuria in diabetic hypertensives with microalbuminuria

Significant blood pressure reductions seen with Exforge HCT in large trial

Phase II data on CP-690550 in rheumatoid arthritis reported; phase III program begins

European CHMP recommends approval of Centocor Ortho Biotech's Simponi for RA, PsA and AS

Gilead receives positive opinion from European CHMP for aztreonam lysine in CF

FDA Committee recommends Bepreve for itching associated with conjunctivitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 9, 2025.
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
Omada, Caris arrivals continue med-tech IPO hot streak
BioWorld MedTech
Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...